Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Overview of attention for article published in New England Journal of Medicine, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 16 news outlets
blogs: 3 blogs
policy: 1 policy source
twitter: 551 X users
facebook: 16 Facebook pages

f1000: 1 research highlight platform
guideline: 12 clinical guideline sources
bluesky: 1 Bluesky user
podcasts: 5 podcasts

Readers on

mendeley: 1132 Mendeley

So far, Altmetric has seen 34 news stories from 16 outlets.

Dual therapy best for AFib with ACS no matter the treatment strategy

Pediatric News , 18 Sep 2026

SAN FRANCISCO – Anticoagulation with apixaban and a P2Y12 inhibitor without aspirin provides superior safety and similar…

AUGUSTUS: Apixaban surpassed warfarin despite prior stroke or thromboembolism

Pediatric News , 26 Aug 2026

LOS ANGELES – The edge that the direct-acting oral anticoagulant apixaban (Eliquis) has over warfarin for safely preventing…

AUGUSTUS: After ACS or PCI, aspirin gives AFib patients scant benefit

Pediatric News , 22 Apr 2025

Patients randomized to receive aspirin in addition to an anticoagulant, either apixaban or a vitamin K antagonist such as…

Antithrombotic therapy for atrial fibrillation and ACS or PCI: choosing a regimen based on the totality of events

Medicine Today, 15 Apr 2025

Trial data examining total events, not just first events, support choosing apixaban over warfarin and holding aspirin while…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 30 additional news stories.